# Imax Corp: financial statements, quarterly

IMAX · NYSE · CIK 921582 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/imax.md) · [Financials](/companies/imax/financials.md) · [Filings](/companies/imax/filings.md) · [Insiders](/companies/imax/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/imax/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [104](/filings/0000921582-24-000022.md) | [86.0 d](/filings/0001628280-26-011770.md) | [79.1](/filings/0000921582-25-000025.md) | [89.0](/filings/0000921582-25-000067.md) | [91.5](/filings/0001628280-25-045982.md) | [92.7 d](/filings/0001628280-26-011770.md) | [86.7](/filings/0001628280-26-028960.md) | [91.7](/filings/0001628280-26-049300.md) | [107](/filings/0001628280-25-045982.md) | [125 d](/filings/0001628280-26-011770.md) | [81.4](/filings/0001628280-26-028960.md) | [103](/filings/0001628280-26-049300.md) |
| Cost of revenue | $m | [41.2](/filings/0000921582-24-000022.md) | [42.3 d](/filings/0001628280-26-011770.md) | [32.2](/filings/0000921582-25-000025.md) | [45.0](/filings/0000921582-25-000067.md) | [40.4](/filings/0001628280-25-045982.md) | [44.3 d](/filings/0001628280-26-011770.md) | [33.5](/filings/0001628280-26-028960.md) | [38.1](/filings/0001628280-26-049300.md) | [39.4](/filings/0001628280-25-045982.md) | [53.1 d](/filings/0001628280-26-011770.md) | [35.6](/filings/0001628280-26-028960.md) | [39.9](/filings/0001628280-26-049300.md) |
| Gross profit | $m | [62.7](/filings/0000921582-24-000022.md) | [43.7 d](/filings/0001628280-26-011770.md) | [46.9](/filings/0000921582-25-000025.md) | [43.9](/filings/0000921582-25-000067.md) | [51.0](/filings/0001628280-25-045982.md) | [48.4 d](/filings/0001628280-26-011770.md) | [53.2](/filings/0001628280-26-028960.md) | [53.6](/filings/0001628280-26-049300.md) | [67.3](/filings/0001628280-25-045982.md) | [72.1 d](/filings/0001628280-26-011770.md) | [45.8](/filings/0001628280-26-028960.md) | [62.9](/filings/0001628280-26-049300.md) |
| Research and development | $m | [2.8](/filings/0000921582-24-000022.md) | [2.7 d](/filings/0001628280-26-011770.md) | [2.2](/filings/0000921582-25-000025.md) | [2.0](/filings/0000921582-25-000067.md) | [(0.3) d](/filings/0001628280-25-045982.md) | [1.2 d](/filings/0001628280-26-011770.md) | [1.3](/filings/0001628280-26-028960.md) | [1.5](/filings/0001628280-26-049300.md) | [1.5](/filings/0001628280-25-045982.md) | [1.5 d](/filings/0001628280-26-011770.md) | [1.8](/filings/0001628280-26-028960.md) | [1.7](/filings/0001628280-26-049300.md) |
| Selling, general and administrative | $m | [36.3](/filings/0000921582-24-000022.md) | [35.1 d](/filings/0001628280-26-011770.md) | [31.3](/filings/0000921582-25-000025.md) | [37.6](/filings/0000921582-25-000067.md) | [31.5](/filings/0001628280-25-045982.md) | [32.4 d](/filings/0001628280-26-011770.md) | [33.5](/filings/0001628280-26-028960.md) | [35.3](/filings/0001628280-26-049300.md) | [34.2](/filings/0001628280-25-045982.md) | [35.5 d](/filings/0001628280-26-011770.md) | [32.5](/filings/0001628280-26-028960.md) | [34.5](/filings/0001628280-26-049300.md) |
| Operating income | $m | [22.0](/filings/0000921582-24-000022.md) | [2.7 d](/filings/0001628280-26-011770.md) | [12.1](/filings/0000921582-25-000025.md) | [2.9](/filings/0000921582-25-000067.md) | [19.4](/filings/0001628280-25-045982.md) | [9.5 d](/filings/0001628280-26-011770.md) | [16.7](/filings/0001628280-26-028960.md) | [14.3](/filings/0001628280-26-049300.md) | [29.0](/filings/0001628280-25-045982.md) | [24.1 d](/filings/0001628280-26-011770.md) | [10.0](/filings/0001628280-26-028960.md) | [20.8](/filings/0001628280-26-049300.md) |
| Interest expense | $m | [1.5](/filings/0000950170-23-055032.md) | [1.8 d](/filings/0000950170-24-021327.md) | [1.9](/filings/0000950170-24-047943.md) | [2.3](/filings/0000921582-25-000067.md) | [2.2](/filings/0001628280-25-045982.md) | [1.6 d](/filings/0001628280-26-011770.md) | [1.8](/filings/0001628280-26-028960.md) | [1.9](/filings/0001628280-26-049300.md) | [1.8](/filings/0001628280-25-045982.md) | [1.8 d](/filings/0001628280-26-011770.md) | [1.9](/filings/0001628280-26-028960.md) | [2.0](/filings/0001628280-26-049300.md) |
| Income tax | $m | [6.6](/filings/0000921582-24-000022.md) | [(1.9) d](/filings/0001628280-26-011770.md) | [5.2](/filings/0000921582-25-000025.md) | [(4.0)](/filings/0000921582-25-000067.md) | [2.4](/filings/0001628280-25-045982.md) | [1.5 d](/filings/0001628280-26-011770.md) | [7.3](/filings/0001628280-26-028960.md) | [1.2](/filings/0001628280-26-049300.md) | [5.2](/filings/0001628280-25-045982.md) | [4.1 d](/filings/0001628280-26-011770.md) | [2.4](/filings/0001628280-26-028960.md) | [3.5](/filings/0001628280-26-049300.md) |
| Net income | $m | [12.0](/filings/0000921582-24-000022.md) | [2.5 d](/filings/0001628280-26-011770.md) | [3.3](/filings/0000921582-25-000025.md) | [3.6](/filings/0000921582-25-000067.md) | [13.9](/filings/0001628280-25-045982.md) | [5.3 d](/filings/0001628280-26-011770.md) | [2.3](/filings/0001628280-26-028960.md) | [11.3](/filings/0001628280-26-049300.md) | [20.7](/filings/0001628280-25-045982.md) | [0.6 d](/filings/0001628280-26-011770.md) | [4.2](/filings/0001628280-26-028960.md) | [15.4](/filings/0001628280-26-049300.md) |
| Diluted EPS | $ per share | [0.22](/filings/0000921582-24-000022.md) | not reported | [0.06](/filings/0000921582-25-000025.md) | [0.07](/filings/0000921582-25-000067.md) | [0.26](/filings/0001628280-25-045982.md) | not reported | [0.04](/filings/0001628280-26-028960.md) | [0.20](/filings/0001628280-26-049300.md) | [0.37](/filings/0001628280-25-045982.md) | not reported | [0.07](/filings/0001628280-26-028960.md) | [0.27](/filings/0001628280-26-049300.md) |
| Basic EPS | $ per share | [0.22](/filings/0000921582-24-000022.md) | not reported | [0.06](/filings/0000921582-25-000025.md) | [0.07](/filings/0000921582-25-000067.md) | [0.26](/filings/0001628280-25-045982.md) | not reported | [0.04](/filings/0001628280-26-028960.md) | [0.21](/filings/0001628280-26-049300.md) | [0.38](/filings/0001628280-25-045982.md) | not reported | [0.08](/filings/0001628280-26-028960.md) | [0.28](/filings/0001628280-26-049300.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [110](/filings/0000950170-23-055032.md) | [76.2](/filings/0000921582-25-000008.md) | [81.0](/filings/0000950170-24-047943.md) | [91.6](/filings/0000921582-24-000010.md) | [105](/filings/0000921582-24-000022.md) | [101](/filings/0001628280-26-011770.md) | [97.1](/filings/0000921582-25-000025.md) | [109](/filings/0000921582-25-000067.md) | [143](/filings/0001628280-25-045982.md) | [151](/filings/0001628280-26-049300.md) | [146](/filings/0001628280-26-028960.md) | [160](/filings/0001628280-26-049300.md) |
| Total assets | $m | [851](/filings/0000950170-23-055032.md) | [815](/filings/0000921582-25-000008.md) | [824](/filings/0000950170-24-047943.md) | [827](/filings/0000921582-24-000010.md) | [848](/filings/0000921582-24-000022.md) | [830](/filings/0001628280-26-011770.md) | [848](/filings/0000921582-25-000025.md) | [869](/filings/0000921582-25-000067.md) | [890](/filings/0001628280-25-045982.md) | [894](/filings/0001628280-26-049300.md) | [893](/filings/0001628280-26-028960.md) | [918](/filings/0001628280-26-049300.md) |
| Total liabilities | $m | [494](/filings/0000950170-23-055032.md) | [469](/filings/0000921582-25-000008.md) | [491](/filings/0000950170-24-047943.md) | [484](/filings/0000921582-24-000010.md) | [480](/filings/0000921582-24-000022.md) | [452](/filings/0001628280-26-011770.md) | [464](/filings/0000921582-25-000025.md) | [464](/filings/0000921582-25-000067.md) | [453](/filings/0001628280-25-045982.md) | [466](/filings/0001628280-26-049300.md) | [465](/filings/0001628280-26-028960.md) | [467](/filings/0001628280-26-049300.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [287](/filings/0000950170-23-055032.md) | [273](/filings/0000921582-25-000008.md) | [259](/filings/0000950170-24-047943.md) | [267](/filings/0000921582-24-000010.md) | [289](/filings/0000921582-24-000022.md) | [299](/filings/0001628280-26-011770.md) | [300](/filings/0000921582-25-000025.md) | [320](/filings/0000921582-25-000067.md) | [350](/filings/0001628280-25-045982.md) | [338](/filings/0001628280-26-049300.md) | [335](/filings/0001628280-26-028960.md) | [356](/filings/0001628280-26-049300.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Total assets: us-gaap:Assets
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [28.8 d](/filings/0000921582-24-000022.md) | [4.0 d](/filings/0001628280-26-011770.md) | [(11.0)](/filings/0000921582-25-000025.md) | [35.0 d](/filings/0000921582-25-000067.md) | [35.3 d](/filings/0001628280-25-045982.md) | [11.5 d](/filings/0001628280-26-011770.md) | [7.0](/filings/0001628280-26-028960.md) | [23.2 d](/filings/0001628280-26-049300.md) | [67.5 d](/filings/0001628280-25-045982.md) | [29.4 d](/filings/0001628280-26-011770.md) | [4.0](/filings/0001628280-26-028960.md) | [32.0 d](/filings/0001628280-26-049300.md) |
| Capital expenditure | $m | [1.5 d](/filings/0000921582-24-000022.md) | [4.0 d](/filings/0001628280-26-011770.md) | [1.1](/filings/0000921582-25-000025.md) | [1.6 d](/filings/0000921582-25-000067.md) | [1.1 d](/filings/0001628280-25-045982.md) | [4.6 d](/filings/0001628280-26-011770.md) | [1.6](/filings/0001628280-26-028960.md) | [2.4 d](/filings/0001628280-26-049300.md) | [2.7 d](/filings/0001628280-25-045982.md) | [1.4 d](/filings/0001628280-26-011770.md) | [2.1](/filings/0001628280-26-028960.md) | [0.0 d](/filings/0001628280-26-049300.md) |
| Share repurchases | $m | [0.3 d](/filings/0000921582-24-000022.md) | not reported | [17.9](/filings/0000921582-25-000025.md) | [0.2 d](/filings/0000921582-24-000010.md) | [0.0 d](/filings/0000921582-24-000022.md) | not reported | [0.0](/filings/0000921582-25-000025.md) | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [56.0](/filings/0000950170-23-055032.md) | [55.0](/filings/0000950170-24-047943.md) | [55.3](/filings/0000921582-24-000010.md) | [55.5](/filings/0000921582-24-000022.md) | [53.4](/filings/0000921582-25-000025.md) | [53.4](/filings/0000921582-25-000067.md) | [54.1](/filings/0001628280-25-045982.md) | [55.0](/filings/0001628280-26-028960.md) | [55.2](/filings/0001628280-26-049300.md) | [55.6](/filings/0001628280-25-045982.md) | [56.4](/filings/0001628280-26-028960.md) | [56.6](/filings/0001628280-26-049300.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 54,842,114 at 2026-06-30, from the cover of the [10-Q filed 2026-07-23](/filings/0001628280-26-049300.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:28 ET. No prices; not investment advice.